EP
ZNTL icon

Eversept Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Eversept Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-38,342
Closed -$1.08M – 86
2022
Q2 		$1.08M Sell
38,342
-61,845
-62% -$1.64M 0.08% 65
2022
Q1 		$4.62M Buy
100,187
+37,024
+59% +$2M 0.36% 47
2021
Q4 		$5.31M Buy
+63,163
New +$4.89M 0.34% 63

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Eversept Partners's ZNTL Position: Q3 2022 in Review

Eversept Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2022, closing a stake of 38,342 shares — an estimated $1.08M sold.

Eversept Partners first reported a position in ZNTL in Q4 2021 and held it in 3 quarters. The position peaked at $5.31M in Q4 2021. 120 funds tracked by Wall St. Rank hold ZNTL as of Q3 2022.

  • Eversept Partners reported no remaining Zentalis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Eversept Partners sold 38,342 Zentalis Pharmaceuticals shares in Q3 2022, an estimated $1.08M.
  • Eversept Partners first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Eversept Partners's Zentalis Pharmaceuticals position peaked at $5.31M in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2022.

Based on Eversept Partners's 13F filing for Q3 2022, filed 14 Nov 2022.